Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRxâ"¢ into pharmacy client point-of-sales systems has commenced EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026 Manufacturer supplier relationship expansion effort focused on d ...

TAMPA, FL / ACCESS Newswire / December 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx â"¢ into its patented blockchain-enabled smart contracts platform PharmacyChainâ"¢, today reminded shareholders of the December 19, 2025 record date (the "Record Date") to receive Dream Bowl 2026 Meme Coin ("Dream Bowl") tokens. All eligible record holders of Wellg ...

Core Insights - Wellgistics Health, Inc. has launched the diabetes prescription drug Brenzavvy® targeting 33 million Americans diagnosed with type II diabetes, primarily through its network of 6,500 independent pharmacies [1][4] - The SGLT-2 inhibitor market, which includes drugs like Jardiance®, reached sales of $16.8 billion in 2024 and is projected to grow to $28.9 billion by 2033, with the U.S. accounting for 40.8% of this market [2][4] - The proprietary EinsteinRx™ artificial intelligence platform will assist pharmacists in optimizing therapy selection and educating providers about Brenzavvy's benefits compared to other SGLT-2 inhibitors [2][3] Company Overview - Wellgistics Health integrates its EinsteinRx™ AI platform with a blockchain-enabled smart contracts platform, PharmacyChain™, to enhance the prescription drug dispensing process [4][5] - The company aims to improve patient access to medications while providing revenue opportunities for pharmacists through patient education on Brenzavvy [3][4] - The launch of Brenzavvy establishes a new model for next-generation drugs that offer specific advantages over established market leaders [4] Market Context - A significant gap exists in the prescription of SGLT-2 inhibitors, with only 11.9% of eligible diabetic patients receiving guideline-recommended prescriptions, indicating a need for improved care [2] - The launch of Brenzavvy is positioned to address the high out-of-pocket costs faced by many patients, particularly those who are uninsured or underinsured [4]

TAMPA, FLORIDA / ACCESS Newswire / December 4, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader implementing EinsteinRxâ"¢ artificial intelligence prescription drug routing into blockchain-enabled smart contracts platform PharmacyChainâ"¢ to optimize the prescription medicines reimbursement and dispensing journey, today announced that it set a record date of December 19, 2025 for determining stockholders entitled to receive the Dream Bowl 2026 Meme Coin. ...

Group 1 - The company plans to distribute Dream Bowl 2026 Meme Coin to shareholders with a record date and distribution date expected in December 2025 [1] - Distribution of the Meme Coin is anticipated to occur in January 2026 [1] - Wellgistics Health, Inc. is involved in the DataVault AI Shareholder Distribution Plan and is sponsoring Dream Bowl 2026 [1] Group 2 - Wellgistics is a leader in health information technology, utilizing EinsteinRx™ artificial intelligence for prescription routing [1] - The company employs PharmacyChain™ blockchain-enabled smart contracts to enhance the tracking and dispensing of prescription drugs [1] - The technology aims to optimize insurance coverage from manufacturers to patients [1]

Core Insights - Wellgistics is positioned to lead in the Web 3.0 Health Information Data Transfer within the $634 billion prescription drug industry through an exclusive licensing agreement with Datavault AI [1][2][6] - The implementation of Wellgistics' EinsteinRx AI hub is expected to optimize automated prescription fulfillment for various stakeholders including manufacturers, pharmacies, and patients [1][4][6] - Datavault's intellectual property enables smart contracts that create a barrier to entry in the $4.9 trillion US healthcare market [1][2] Company Overview - Wellgistics Health, based in Tampa, Florida, specializes in optimizing medication delivery from manufacturers to patients, connecting over 6,500 pharmacies and 200 manufacturers [3][9] - The PharmacyChain initiative aims to digitize the tracking of prescription drugs, ensuring accurate delivery and recommendations for safe use [3][5] Technology and Innovation - The completion of the EinsteinRx AI hub integrates Wellgistics' IT and physical infrastructure, enhancing the efficiency of prescription fulfillment and reducing costs associated with pharmacy benefits managers (PBMs) [4][5][6] - Wellgistics aims to minimize or eliminate PBM rebates, thereby reducing administrative burdens for payers and improving the overall pharmaceutical distribution process [6][7] Market Potential - PwC estimates a $1 trillion opportunity to shift healthcare spending towards a digital-first, proactive, and personalized system [2] - The integration of smart contracts into Wellgistics' operations is expected to significantly improve cost efficiency in the prescription filling process, benefiting various stakeholders in the healthcare ecosystem [6][7]

Financial Results - Wellgistics Health, Inc. reported financial results for the quarter ended September 30, 2025, with a press release issued on November 20, 2025[5]. - The press release includes forward-looking statements regarding the company's projects and potential financial performance[9]. - The press release is attached as Exhibit 99.1, which contains detailed financial results and operational insights[11]. Company Classification and Regulations - The company is classified as an emerging growth company under the Securities Act of 1933[4]. - The company’s Registration Statement on Form S-1 was declared effective by the SEC on September 25, 2025, discussing various risks associated with forward-looking statements[9]. Financial Metrics and Guidance - The company has not yet disclosed specific financial metrics or performance indicators in the provided documents[5]. - The company has not provided specific guidance or outlook for future performance in the available documents[5]. Company Information - The company’s principal executive offices are located in Tampa, FL[1]. - The trading symbol for Wellgistics Health, Inc. is WGRX, listed on The Nasdaq Capital Market LLC[3]. Product and Market Information - The report does not include any information on new products, technologies, market expansion, or acquisitions[5].

TAMPA, FL / ACCESS Newswire / November 20, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization of healthcare technology infrastructure into the individual patient fulfillment of prescription drug through pharmacies 'From Manufacturer To Patient', today reported financial results for the period ended September 30, 2025 on Form 10-Q on November 19, 2025 [1] and provided a business update from the CEO. "The last 6 weeks have really ...

Revenue Generation and Market Overview - Wellgistics Health expects to generate revenues primarily through Wellgistics Pharmacy and Wellgistics LLC after acquiring Wood Sage, LLC in June 2024 and Wellgistics, LLC in August 2024[182]. - The National Health Expenditure Data for 2022 reached $4.5 trillion, accounting for 17.3% of GDP, with an expected increase to 19.7% by 2032[184]. - Total retail prescription drug spending increased by 8.4% from 2021 to 2022, reaching $405.9 billion[184]. - The U.S. market for medicines reached $435 billion in 2023, with the specialty drug market accounting for over 50% of prescription drug spending despite being less than 10% of total drugs[184]. - Wellgistics, LLC serves over 5,000 registered pharmacies nationwide, focusing on competitive pricing and unique products[172]. - Wellgistics Pharmacy is licensed in 32 states and the District of Columbia, expanding its operations to include mail order pharmacy services[178]. - The pharmacy network includes over 19,000 independent pharmacies across the U.S., capable of delivering prescriptions in hours, servicing approximately 1.3 billion prescriptions annually[185]. - Wellgistics Health aims to enhance patient outcomes by improving medication adherence and providing access to clinical resources[185]. - The company plans to expand its wholesale operations and establish new manufacturer relationships to maximize revenues[185]. Financial Performance - Net revenues for the three months ended September 30, 2025, were $3,012,904, a decrease of approximately 47% compared to $5,673,868 for the same period in 2024[198]. - Gross profit for the three months ended September 30, 2025, was $231,012, representing a decline of approximately 56% from $521,244 in 2024[200]. - General and administrative expenses for the three months ended September 30, 2025, increased to $30,172,800 from $1,798,641 in 2024, primarily due to the acquisition of Wellgistics LLC[202]. - Sales and marketing expenses for the three months ended September 30, 2025, were $803,747, compared to $0 for the same period in 2024, reflecting expanded promotional activities[203]. - Net revenues for the nine months ended September 30, 2025, were $21,667,212, compared to $5,718,408 for the same period in 2024, driven by acquisitions[209]. - Gross profit for the nine months ended September 30, 2025, was $1,429,405, an increase of approximately 176% from $518,636 in 2024[211]. - General and administrative expenses for the nine months ended September 30, 2025, were $66,205,669, up from $2,448,813 in 2024, largely due to acquisitions[214]. - Interest expense for the nine months ended September 30, 2025, was $3,703,837, compared to $142,281 in 2024, reflecting increased financing activities[218]. - The significant increase in other expenses for the nine months ended September 30, 2025, totaled $5,024,498, compared to $126,874 in 2024, primarily due to interest expenses and losses related to acquisitions[217]. - The Company recognized a loss of $1,353,663 for the nine months ended September 30, 2025, due to the amendment of the Membership Interest Purchase Agreement, increasing the promissory note from $15 million to $17.5 million[219]. Debt and Financing Activities - As of September 30, 2025, total debt amounted to $24,809,234, an increase from $23,382,901 as of December 31, 2024[225]. - The Company expects to generate positive cash flow from operations in 2025, driven by annual revenue from Wood Sage and Wellgistics LLC[220]. - The Company issued a total of 3,426,254 shares of common stock, resulting in net proceeds of $2,838,787 as of September 30, 2025[223]. - A public offering of 7,142,862 shares of common stock was filed on September 29, 2025, generating net proceeds of approximately $4.53 million[224]. - The Company entered into a secured term loan of $1,300,000 on August 26, 2025, with a total repayment obligation of $1,872,000[231]. - The Company recorded interest expenses of $668,148 for the nine months ended September 30, 2025, related to various debt instruments[230]. - The Company plans to use proceeds from offerings to strengthen working capital, support operations, and pursue strategic acquisitions[224]. - The Company has ongoing initiatives for facility expansion, employee recruitment, and technology upgrades to meet operational needs[221]. - The Company is focusing on strategic acquisitions to enhance its health ecosystem, including investments in artificial intelligence and data warehousing capabilities[222]. - Wellgistics, LLC entered into a new credit agreement for a line of credit of $10,000,000 with an annual interest rate of 16.84%[241]. - As of September 30, 2025, the outstanding balance on the line of credit was $2,973,751, down from $5,531,260 as of December 31, 2024[241]. Cash Flow and Investment Activities - Net cash used in operating activities for the nine months ended September 30, 2025 was $4,561,776, primarily due to a net loss of $72,981,336[247]. - Net cash provided by financing activities for the nine months ended September 30, 2025 was $8,388,250, driven by gross proceeds of $4,000,000 from the IPO and $20,070,000 from the revolving line of credit[250]. - The company fully repaid the $1.2 million promissory note as of September 30, 2025, compared to an outstanding balance of $137,141 as of December 31, 2024[243]. - The company plans to retain future earnings for operations, expansion, and debt repayment, with no current plans to pay cash dividends[245]. - Net cash used in investing activities for the nine months ended September 30, 2025 was $626,144, primarily for capitalized software expenditures[249]. Accounting and Revenue Recognition - The company recognized revenue at the point of sale, with the majority of orders placed via its website[256]. - The company accounts for acquisitions as business combinations, allocating the purchase price to the fair values of acquired assets and liabilities[262]. - As of September 30, 2025, the company had total outstanding debt principal payments of $24,809,234 scheduled through 2028[244].

TAMPA, FL / ACCESS Newswire / November 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of the physical and technology healthcare infrastructures for prescription drug distribution from manufacturer to patient through licensed pharmacies, today announced that it will report third quarter 2025 provide a business update and report financial results for the period ended September 30, 2025 on the morning of Thursday, November 20, 2025. About ...